dc.contributor
[Plans-Rubió P] Agència de Salut Pública de Catalunya, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain
dc.contributor
Departament de Salut
dc.contributor.author
NCD Risk Factor Collaboration (NCD-RisC)
dc.contributor.author
Plans-Rubió, Pedro
dc.date.accessioned
2025-10-24T10:57:17Z
dc.date.available
2025-10-24T10:57:17Z
dc.date.issued
2024-05-06T12:46:55Z
dc.date.issued
2024-05-06T12:46:55Z
dc.date.issued
2021-09-11
dc.identifier
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021 Sep 11;398(10304):957-980.
dc.identifier
https://hdl.handle.net/11351/11419
dc.identifier
https://doi.org/10.1016/S0140-6736(21)01330-1
dc.identifier.uri
http://hdl.handle.net/11351/11419
dc.description.abstract
Salut mundial; Hipertensió; Adults
dc.description.abstract
Salud mundial; Hipertensión; Adultos
dc.description.abstract
Global health; Hypertension; Adults
dc.description.abstract
Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively
control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment,
and control from 1990 to 2019 for 200 countries and territories.
Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with
measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic
blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for
hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the
proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for
hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model
allowed for trends over time to be non-linear and to vary by age.
Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible
interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698)
million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence
was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries
in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income
countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for
women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and
Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis
of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people
with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates
were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica,
Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal,
Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in
these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and
control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa
and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and
recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran.
Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially
across countries, with some middle-income countries now outperforming most high-income nations. The
dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and
control is achievable not only in high-income countries but also in low-income and middle-income settings.
dc.description.abstract
WHO
dc.format
application/pdf
dc.relation
The Lancet;398(10304)
dc.relation
https://doi.org/10.1016/S0140-6736(21)01330-1
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Hipertensió – Epidemiologia
dc.subject
Hipertensió – Prevenció
dc.subject
HEALTH CARE::Population Characteristics::Health::Global Health
dc.subject
DISEASES::Cardiovascular Diseases::Vascular Diseases::Hypertension
dc.subject
Other subheadings::Other subheadings::Other subheadings::/epidemiology
dc.subject
DISEASES::Cardiovascular Diseases::Vascular Diseases::Hypertension
dc.subject
Other subheadings::Other subheadings::Other subheadings::/prevention & control
dc.subject
NAMED GROUPS::Persons::Age Groups::Adult
dc.subject
ATENCIÓN DE SALUD::Características de la Población::salud::salud global
dc.subject
ENFERMEDADES::enfermedades cardiovasculares::enfermedades vasculares::hipertensión
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/epidemiología
dc.subject
ENFERMEDADES::enfermedades cardiovasculares::enfermedades vasculares::hipertensión
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control
dc.subject
DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::adulto
dc.title
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion